Goldman predicts setbacks for Genzyme

Goldman Sachs added Genzyme to its Americas conviction sell list, saying that manufacturing setbacks at one of its plants may impair long-term growth at the company, and a near-term shortage of its drug Cerezyme may be more severe than expected. Report

Suggested Articles

Compared with the FDA "boxed warning," the EMA version puts a smaller restriction on the higher dose but broadens the cautionary language.

Shionogi's newest antibiotic Fetroja has now earned the FDA's approval, but will a mortality-rate warning scuttle the drug's chances?

Novartis' Sandoz doubled down in Japan as Lupin retreated. Dr. Reddy's posted a loss tied to its Zantac recall. Aslan's varlitinib failed again.